The skin barrier is broadly composed of two elements—a physical barrier mostly localised in
the epidermis, and an immune barrier localised in both the dermis and epidermis. These two …

Personalized medicine is the new frontier in psoriasis as it may allow a patient-tailored
management with treatment optimization and reduction of side effects as well as health costs …

Over the past three decades, many methods have been developed to evaluate levels of
biomarkers in autoimmune diseases. Early investigations have shown that some biomarkers …

Background: Psoriasis is a common chronic inflammatory skin disease with an exceptionally
high burden for women. Objective: Sex-dependent differences in disease manifestation …

Pharmacogenomic studies allowed the reasons behind the different responses to treatments
to be understood. Its clinical utility, in fact, is demonstrated by the reduction in adverse drug …

Psoriasis is a chronic inflammatory disease with an established genetic background. The
HLA-Cw* 06 allele and different polymorphisms in genes involved in inflammatory …

The efficacy and the safety of psoriasis medications have been proved in trials, but unideal
responses and side effects are noted in clinical practice. Genetic predisposition is known to …

The genetic polymorphisms rs2395185 and rs2097432 in HLA genes have been associated
with the response to anti-TNF treatment in inflammatory bowel disease (IBD). The aim was to …

Introduction Dose escalation and reduction of biologic treatments are frequent in clinical
practice. The aim of this systematic review is to summarise evidence on dose adjustment of …

Psoriasis is an erythematous-squamous dermatosis with a polygenic inheritance history.
Both environmental and genetic factors play a role in the etiology of the disease. Over the …